MedTrace Logo

Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy

NCT07453095 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2026-04-17

No results posted yet for this study

Summary

This is a Phase 2, multicentre, single arm study that evaluates the efficacy and safety of glofitamab in MCL patients with inadequate response or relapse following CAR T-cell therapy.

Conditions

Interventions

DRUG

Glofitamab

Glofitamab treatment in post CAR-T R/R MCL patients

Sponsors & Collaborators

  • Fondazione Italiana Linfomi - ETS

    lead OTHER

Principal Investigators

  • Marco Ladetto, Prof · Dipartimento Medicina Traslazionale, Università del Piemonte Orientale - S.C. Ematologia ed Infrastruttura Ricerca Formazione ed Innovazione, A.O. SS. Antonio e Biagio e C. Arrigo (Alessandria, Italy)

  • Rita Tavarozzi, MD · Dipartimento Medicina Traslazionale, Università del Piemonte Orientale - S.C. Ematologia ed Infrastruttura Ricerca Formazione ed Innovazione, A.O. SS. Antonio e Biagio e C. Arrigo (Alessandria, Italy)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-15
Primary Completion
2028-07-15
Completion
2030-06-15

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07453095 on ClinicalTrials.gov